Previous close | 1.9800 |
Open | 1.9700 |
Bid | 1.9000 x 7600 |
Ask | 1.9300 x 7600 |
Day's range | 1.8601 - 2.0250 |
52-week range | 0.3450 - 2.1050 |
Volume | |
Avg. volume | 10,406,625 |
Market cap | 491.496M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.